Analysts positive on US prospects for tivozanib but data request weighs on Aveo stock
This article was originally published in Scrip
Executive Summary
It's hard to say whether investors were reacting more to Aveo Oncology's larger net loss or news that the US FDA had asked for more data on overall survival rates versus Nexavar (sorafenib) for the US company's Phase III kidney cancer drug and lead product candidate tivozanib, but the firm's stock price fell 26.8% when it announced second quarter 2012 earnings on 2 August.
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).